ストックスクリーナーアプリを入手
0.8151
29.50%
0.1741
前日終値:
$0.641
開ける：
$0.63
24時間の取引高:
8.20M
Relative Volume:
0.55
時価総額：
$11.07M
収益：
-
当期純損益:
$-12.89M
株価収益率:
-0.3222
EPS:
-2.53
ネットキャッシュフロー:
$-11.95M
1週間 パフォーマンス:
+27.51%
1か月 パフォーマンス:
-29.65%
6か月 パフォーマンス:
-39.97%
1年 パフォーマンス:
-49.99%
1日の値動き範囲:
$0.6107
$0.95
1週間の範囲:
$0.61
$0.95
52週間の値動き範囲:
$0.284
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
PSTV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.8107 | 11.07M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.29 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.31 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.60 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.54 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-17 | 開始されました | D. Boral Capital | Buy |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-16 | 開始されました | Maxim Group | Buy |
Plus Therapeutics Inc (PSTV) 最新ニュース
Plus Therapeutics (NASDAQ:PSTV) Price Target Raised to $20.00 at Ascendiant Capital Markets - Defense World
Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Rises By 34.5% - Defense World
Plus Therapeutics Appoints Kyle Guse to Board - MSN
Plus Therapeutics reports progress in CNS cancer treatment By Investing.com - Investing.com Canada
Plus Therapeutics Inc (NASDAQ: PSTV) Analysts Expect It Could Climb 89.63% From Current Levels. - stocksregister.com
Plus Therapeutics Presents New Data Highlighting Clinical Benefi - GuruFocus
Plus Therapeutics (PSTV) Unveils Promising Data on REYOBIQ at Upcoming Conference | PSTV Stock News - GuruFocus
Plus Therapeutics reports progress in CNS cancer treatment - Investing.com
Plus Therapeutics Presents New Data Highlighting Clinical - GlobeNewswire
New Cancer Drug REYOBIQ Achieves Breakthrough 86% Clinical Benefit in Brain Metastases Study - Stock Titan
Plus Therapeutics (PSTV) Plans Massive Stock Sale - GuruFocus
Plus Therapeutics Inc (PSTV) Volatility Hits 17.12% – Here Is What You Should Do - Stocksregister
Promising Outlook for Plus Therapeutics: Buy Rating Affirmed Amid Clinical and Financial Advancements - TipRanks
Plus Therapeutics: What’s Fueling the Surge? - timothysykes.com
PLUS THERAPEUTICS Inc. (PSTV) reports earnings - Quartz
What is HC Wainwright’s Estimate for PSTV FY2029 Earnings? - Defense World
HC Wainwright Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price - Defense World
Plus Therapeutics (NASDAQ:PSTV) Earns “Buy” Rating from D. Boral Capital - Defense World
Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL
Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Canada
Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating - TipRanks
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: S - GuruFocus
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Plus Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Plus Therapeutics (PSTV) Reports Mixed FY Results, Revenue Surges - GuruFocus
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Plus Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PLUS THERAPEUTICS Earnings Results: $PSTV Reports Quarterly Earnings - Nasdaq
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
A Peek at Plus Therapeutics's Future Earnings - Benzinga
PLUS THERAPEUTICS Earnings Preview: Recent $PSTV Insider Trading, Hedge Fund Activity, and More - Nasdaq
Plus Therapeutics Introduces REYOBIQ - citybiz
Top Small Cap Stocks To Watch TodayMarch 20th - MarketBeat
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug - TradingView
Thursday's Trending Pharma Stock Plus Therapeutics, Inc. (Nasdaq: PSTV) Gains 170% - Investorideas.com
Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? - Insider Monkey
10 Micro-, Small-Cap Firms Dominate Thursday’s Gains - Insider Monkey
Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate - Marketscreener.com
FDA conditionally accepts new name for Plus Therapeutics drug By Investing.com - Investing.com South Africa
Plus Therapeutics announces FDA conditionally accepted name REYOBIQ - TipRanks
FDA conditionally accepts new name for Plus Therapeutics drug - Investing.com India
Why Plus Therapeutics Is Rising In Pre-market? - Nasdaq
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate - GlobeNewswire
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - StockTitan
Plus Therapeutics Inc (PSTV) 財務データ
収益
当期純利益
現金流量
EPS
Plus Therapeutics Inc (PSTV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
5,717 |
| HEDRICK MARC H | Chief Executive Officer |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
12,425 |
| Petersen Greg | Director |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
36,421 |
| Clowes Howard | Director |
May 08 '24 |
Buy |
2.04 |
9,804 |
20,000 |
21,497 |
| Hawkins Richard J | Director |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
4,903 |
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):